The importance of incorporation of real-world evidence into the guidelines on the pharmacological treatment of schizophrenia.

Istvan Bitter, Lajos Katona, Peter Falkai, Pal Czobor

Abstract read

In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Real-world evidence on antipsychotics may improve schizophrenia treatment.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Istvan BitterDepartment of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. bitter.istvan@semmelweis.hu.ORCID http://orcid.org/0000-0002-9464-4709

Lajos KatonaDepartment of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0001-9929-0543

Peter FalkaiGerman Center for Mental Health (DZPG), Munich, Germany.ORCID http://orcid.org/0000-0003-2873-8667

Pal CzoborDepartment of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0002-6361-8006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quantity and quality of real-world data and real-world evidence in schizophrenia research are at a high level. However, these results are not included in the grading systems used to develop treatment guidelines for schizophrenia. A meta-analysis and a network meta-analysis have independently provided evidence that the results of randomized clinical trials in schizophrenia adequately translate to real-world settings. The authors propose the incorporation of a synthesis of evidence derived from analyses of randomized controlled trials and real-world data as a novel and highest level of evidence in grading instruments used to develop treatment guidelines for schizophrenia.

Indexed as

Antipsychotic AgentsEvidence-Based MedicineSchizophreniaHumansPractice Guidelines as TopicRandomized Controlled Trials as TopicAntipsychotic AgentsGuidelinesRandomized clinical trialsReal-world dataReal-world evidenceSchizophrenia

Identifiers

PMID39535551

DOI10.1007/s00406-024-01938-1

PMCPMC12270948

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.